INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 239S · 10 late239 trades$59.22M
  2. 02SPSaba Capital Management, L.P.68B / 23S · 14 late91 trades$30.01M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07CFCheng Chi Fung0B / 42S42 trades$15.33M
  8. 08RJRubinstein Julie0B / 37S37 trades$6.25M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  5. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  6. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  7. SELLADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
  8. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K

Form 4 transactions

21,973 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
34
GT
Gilbert Edward Terrell JrGC & CORPORATE SECRETARY
ASTEASTEC INDUSTRIES INC
Open-market sale
SELL$60K
975 sh
Mar 3, 2026
Page 380 of 550
← PrevNext →
Mar 6, 2026
traded Mar 3, 2026
+3d
SEC Form 4

Evidence

32
TD
Tan DerekSR VP Chief Accounting Officer
WCNWaste Connections, Inc.
Open-market sale
SELL$201K
1,173 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

32
GG
Gibson GuyCo-President Asset Servicing
NTRSNORTHERN TRUST CORP
Open-market sale
SELL$428K
3,009 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

28
HD
Hahnfeld Jeffrey DEVP-CONTROLLER & CHIEF ACC OFF
WTFCWINTRUST FINANCIAL CORP
Open-market sale
SELL$77K
530 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

28
WM
Willrath MatthewVP & CAO
GPORGULFPORT ENERGY CORP
Open-market sale
SELL$107K
497 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

26
FN
Fryer NeilVP and GM Global Aftermarket
PHINPHINIA INC.
Open-market sale
SELL$45K
624 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

24
MJ
Martin Ryan JSVP Finance
AEEAMEREN CORP
Open-market sale
SELL$147K
1,300 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
RN
Ramanan NatarajanChief Technology Officer
ERIIEnergy Recovery, Inc.
Open-market sale
SELL$2,875
272 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

21
HS
Hershkowitz StevenEVP & Chief Revenue Officer
RMNIRimini Street, Inc.
Open-market sale
SELL$6,222
1,708 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$301K
1,446 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
HS
Hershkowitz StevenEVP & Chief Revenue Officer
RMNIRimini Street, Inc.
Open-market sale
SELL$13K
3,485 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$329K
1,588 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$713K
3,413 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

21
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$511K
2,457 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

20
RJ
Riley JanelChief Accounting Officer
NETCloudflare, Inc.
Open-market sale · 10b5-1 plan
SELL$4.43M
23.3K sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$60K
3,369 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

19
KP
Kozanian PanosEVP, Product Engineering
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$69K
3,860 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$87K
4,924 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
KP
Kozanian PanosEVP, Product Engineering
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
7,002 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
LM
Lee Bryan MChief Financial Officer
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$174K
9,855 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

19
FJ
Fitzpatrick JenniferChief Legal Officer
SIONSionna Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$347K
10.3K sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$239K
1,142 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$127K
612 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$61K
300 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$94K
460 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$70K
340 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

17
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$300K
1,457 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

16
LM
Lee Bryan MChief Financial Officer
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
1,756 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
207 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$411K
1,883 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$866K
4,029 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$389K
1,848 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
200 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$19K
93 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$140K
698 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$141K
697 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192K
950 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$136K
668 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence